Cargando…

Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137

Medulloblastoma (MB) is the most common malignant pediatric brain tumor that can be categorized into four major molecular subgroups. Group 3 MB with MYC amplification (MYCamp-G3-MB) has been shown to be highly aggressive and exhibited worst prognosis, indicating the need for novel effective therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jiajia, Sui, Yi, Li, Qifeng, Zhao, Yang, Dong, Xiaoshu, Yang, Jian, Liang, Zhuangzhuang, Han, Yipeng, Tang, Yujie, Ma, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710710/ https://www.ncbi.nlm.nih.gov/pubmed/33268769 http://dx.doi.org/10.1038/s41419-020-03201-6

Ejemplares similares

EMBR-06. EFFECTIVE INHIBITION OF MYC-AMPLIFIFIED GROUP 3 MEDULLOBLASTOMA BY FACT-TARGETED CURAXIN DRUG CBL0137
por: Wang, Jiajia, et al.
Publicado: (2021)

MBRS-62. CURAXIN CBL0137 INHIBITS THE VIABILITY OF CANCEROUS CELLS IN PRE-CLINIC MODELS OF MYC-AMPLIFIED MEDULLOBLASTOMA
por: Wang, Jiajia, et al.
Publicado: (2020)

Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
por: Jin, Ming-Zhu, et al.
Publicado: (2018)

Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers
por: Dallavalle, Sabrina, et al.
Publicado: (2021)

Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo
por: Fetisov, Timur I., et al.
Publicado: (2023)

Insights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins
por: Maksimova, Varvara, et al.
Publicado: (2023)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer
por: Burkhart, Catherine, et al.
Publicado: (2014)

Effective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1
por: Zhao, Yang, et al.
Publicado: (2020)

Mechanism of curaxin-dependent nucleosome unfolding by FACT
por: Volokh, Olesya I., et al.
Publicado: (2022)

Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
por: Singh, Baljinder, et al.
Publicado: (2023)

Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation
por: Jean, Maxime J., et al.
Publicado: (2017)

The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy
por: Lv, Yan, et al.
Publicado: (2023)

Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins
por: Chang, Han-Wen, et al.
Publicado: (2018)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
por: Lindner, Daniel J., et al.
Publicado: (2020)

Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
por: Ecker, Jonas, et al.
Publicado: (2015)

Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma
por: Bharambe, Harish Shrikrishna, et al.
Publicado: (2020)

MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
por: Kameda-Smith, Michelle, et al.
Publicado: (2020)

Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC-Amplified Group 3 Medulloblastoma by Droplet Digital PCR
por: Stepien, Natalia, et al.
Publicado: (2023)

BIOL-10. DISTRIBUTION AND VULNERABILITY OF TRANSCRIPTIONAL OUTPUTS ACROSS THE GENOME IN MYC-AMPLIFIED MEDULLOBLASTOMA CELLS
por: Yang, Rui, et al.
Publicado: (2021)

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma
por: Adiamah, Magretta, et al.
Publicado: (2022)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma
por: Schwinn, Stefanie, et al.
Publicado: (2021)

The anti-cancer drugs curaxins target spatial genome organization
por: Kantidze, Omar L., et al.
Publicado: (2019)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
por: Vollmer, Johanna, et al.
Publicado: (2023)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

IMMU-19. HDAC INHIBITORS SENSITIZE MYC-AMPLIFIED MEDULLOBLASTOMA TO IMMUNOTHERAPY BY ACTIVATING THE NF-kB PATHWAYS
por: Marquardt, Viktoria, et al.
Publicado: (2020)

EHMTI-0137. Headache as an initial clinical symptom of carotid artery dissection
por: Slankamenac, P, et al.
Publicado: (2014)

EMBR-02. OLIG2 REPRESENTS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-AMPLIFIED MEDULLOBLASTOMA RELAPSE AND METASTASIS
por: Xu, Zhenhua, et al.
Publicado: (2021)

Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma
por: Kameda-Smith, Michelle M., et al.
Publicado: (2022)

Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
por: Chaturvedi, Nagendra K., et al.
Publicado: (2019)

Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways
por: Pham, Khoa, et al.
Publicado: (2022)

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA
por: Llargués-Sistac, Gemma, et al.
Publicado: (2020)

Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency
por: Huemer, Martina, et al.
Publicado: (2016)

Author Correction: Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma
por: Kameda-Smith, Michelle M., et al.
Publicado: (2023)

Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis
por: Cao, Liangliang, et al.
Publicado: (2022)

Identification and Functional Characterization of Novel MYC-Regulated Long Noncoding RNAs in Group 3 Medulloblastoma
por: Rea, Jessica, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_saguncfgk000848q8oa7arof6m